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Abstract
Brugada syndrome (BrS) is characterised by the triad of coved ST elevation, lethal ventricular 
arrhythmia in an apparently structurally normal heart. The precise mechanisms responsible for 
the coved ST elevation and ventricular arrhythmias in this disease have been debated since its 
initial description in 1992. Indeed the recent recognition of early repolarisation J wave disorders 
linked to primary VF broadens the mechanistic importance of BrS in sudden cardiac death. It 
may lie on a spectrum of early repolarisation pathology which is becoming increasingly 
recognised as a marker of premature cardiovascular death. Mechanistically, abnormalities of 
both depolarisation and repolarisation in the right ventricular outflow tract, and heterogeneities 
of   conduction   between   the   endocardium   and   epicardium   have   been   implicated   in   the 
electrographic manifestations of BrS and arrhythmogenesis.                                                       
The initial belief of BrS as a single autosomal dominant ion channel disorder has been 
challenged. It has become apparent that sodium channel mutations only account for a maximum 
of 30% of cases and structural myocardial abnormalities have now been described in what was 
previously thought to be a purely functional condition. It is highly probable that BrS is an 
umbrella diagnosis for a number of conduction and repolarisation abnormalities which manifest 
as this syndrome and the coved ST elevation represents the final common pathway of both ion 
channel and structural derangements. This review will discuss the issues surrounding the 
mechanisms of lethal arrhythmia in BrS and summarise both basic science and clinical research 
findings
Keywords:  Brugada   syndrome,   ventricular   arrhyhthmia,   right   ventricular   outflow   tract, 
depolarisation, repolarisation, transmural gradient, sodium channel                           
Introduction
The Brugada syndrome (BrS) was formally characterised as a distinct clinical entity in 1992 [1] 
and is thought to be responsible for 20% of sudden death in people under 50 years of age with 
apparently structurally normal hearts [2]. Inherited in an autosomal dominant fashion with 
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incomplete penetrance, symptoms tend to manifest at an average age of 40 years in the form of 
syncope, nocturnal agonal respiration, ventricular arrhythmia and sudden death [3]. It has a 
significant male preponderance but its true prevalence (estimated at 1-5 in 10,000 worldwide [4] 
is difficult to quantify not only because of its transient signature electrocardiographic signs but 
the failure to correctly identify or report cases of suspected sudden arrhythmic death and the 
lack of subsequent family screening. Ventricular arrhythmia in the syndrome generally takes the 
form of polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF) with the right 
ventricular outflow tract (RVOT) identified as the principal arrhythmogenic site.                      
Abnormalities of repolarisation or depolarisation and heterogeneities in conduction both within 
the epicardium and between the epicardium and endocardium have been proposed to account for 
the electrocardiographic abnormalities and ventricular arrhythmia. There is increasing evidence 
that each of these mechanisms may play a role. BrS as a purely functional ion channel disorder 
is also being questioned by contradictory evidence gathered from cardiac biopsies, autopsy 
specimens and new high resolution imaging modalities.                                                       
A re-entrant mechanism perpetuates ventricular tachycardia in BS, and requires an initiating 
mechanism or 'trigger' and a substrate capable of maintaining it. Since the right ventricular 
outflow   tract   is   the   main   patho-physiological   arena   in   this   disease,   its   structure   and 
embryological   orgins   will   be   reviewed   before   discussing   the   main   hypotheses   of 
arrhythmogenesis  in   BrS.                                                                                    
The Right Ventricular Outflow Tract                                                                   
In Brugada syndrome, the classic ECG findings are present in the right praecordial leads and 
ventricular arhythmias are more readily induced from the right ventricle [5-8]. Moreover, signal 
averaged ECG data, body surface mapping, endocardial and epicardal recordings in the conus 
branch over the RVOT have identified conduction delay in this area [5,9-12]. Extrasystoles 
triggering arrhythmia have also been mapped and ablated in this region [9].                         
The right and left ventricles and RVOT are formed along the craniocaudal axis of the heart 
along which signalling and other critical regulatory processes are polarised. This is suggested to 
account for anatomical differences and electrophysiological heterogeneity in the adult [13]. 
A level of electrophysiological heterogeneity in the heart is vital for optimal cardiac function, 
facilitating   co-ordinated   contraction   and   relaxation.   This   heterogeneity   is   rooted   in 
embryological development and modulated gene expression resulting in regional differences in 
tissue structure and ion channel distribution. Structural and electrophysiological heterogeneities 
exist on multiple levels: (i) between apex and base, (ii) left and right ventricles, (iii) RVOT and 
right ventriclular (RV) body, and (iv) between epicardium and endocardium [13]. Critical 
thresholds in these regional electrophysiological differences exist, which if crossed, lead to 
excessive conduction delays, unidirectional block and re-entry. The stability of the resultant re-
entant circuit is itself dependent upon regional action potential duration (APD) restitution 
properties.
The adult RVOT itself develops from the embryological outflow tract, which is formed at a later 
stage from the rest of the heart, and arises from the second heart field, an origin distinct from the 
ventricles (formed from the first heart field), with added influence from migratory cardiac 
neural crest cells. These developmental differences may account for the RVOT being critical in 
BrS pathogenesis. The program regulating cardiac neural crest development and formation is 
controlled by multiple distinct signals that originate in the pharyngeal endoderm and local 
mesoderm and the neural crest cell death program also plays an active role in stimulating 
outflow tract myocardialization [14-15]. Likewise, Connexin 43 (Cx43) is   involved in the 
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differentiation of some cardiac crest cell lineages; among them, gap junctional communication 
has been linked with the differentiation of cardiac myocytes [16]. Differences in Cx43 
expression exist between the epicardium and mid/endocardium which could lead to transmural 
conduction discontinuites if neural crest migration is disrupted [17]. Significant regional and/or 
transmural differences that arise from such disruptions may contribute mechanistically to the 
principle theories of arrhythmogenesis in BrS: the repolarisation and depolarisation hypotheses.
The Repolarisation  Hypothesis                                                                            
This hypothesis has received its main support from experimental models and posits that 
normally, in contrast to endocardium, the epicardial action potential (AP) has a prominent phase 
1 resulting in a spike and dome morphology [18] (Figure 1A). This is thought to be the result of 
a more pronounced expression in epicardial cells of the transient outward potassium channel 
(ITO), largely responsible for the rapid downstroke of phase 1. If there is a reduction in the 
amplitude of phase 0, this will result in a lower voltage level at which phase 1 begins. This 
affects the activation/inactivation kinetics of both ITO and the availability of the L-type calcium 
channel involved in phase 2, resulting in a loss of the AP dome and shortening of the epicardial 
AP duration (APD). The less pronounced phase 1 downstroke of endocardium due to lower ITO 
expression allows for conservation of the AP pattern, even with some reduction in phase 0 
amplitude (Figure 1B). The transmural gradient during phase 1 between the epicardium and 
endocardium was shown in the canine wedge experiments by Antzelevitch and Yan, to 
contribute to both J point and ST elevation on the surface ECG [18].
The loss of the epicardial AP dome in some areas and retention in others results in the 'trigger' 
mechanism: a closely coupled extrasystole generated by phase 2 re-entry (Figure 1C). The 
increased dispersion of repolarisation between endocardium and epicardium and within the 
epicardium provides a further substrate for maintenance of arrhythmia.                      
Although this heterogeneity in AP duration could account for the corresponding ST changes in
Brugada syndrome, it does not explain the T wave inversion that accompanies type 1 (right 
praecordial coved ST elevation) and sometimes type 2 (right praecordial saddleback ST 
elevation) electrocardiograms. It has been proposed that both an exaggeration of the notch and a 
prolongation of the epicardial AP beyond the endocardial action potential would be necessary to 
observe the raised J point, ST elevation and inverted T wave [18-19] (Figure 1D).
In   Vivo   Human   Studies                                                                                
Although most of the data supportive of the repolarisation hypothesis has been derived from 
pharmacological manipulation of the canine wedge preparation, interesting observations have 
been made in man. Nagase et al reported a patient in whom they had inserted an epicardial 
electrode in the great cardiac vein a small distance from an endocardial catheter [11]. During 
augmented ST elevation, the epicardial but not endocardial activation-recovery interval (ARI - a 
surrogate   of   APD)   shortened.   Kurita   et   al   demonstrated   abnormal   spike   and   dome 
configurations of RVOT epicardial monophasic action potentials (MAPs) in the RVOT of 3 
Brugada patients (all with type 2 ECGs), noting incomplete depolarisation in phases 0 and 1 and 
a deep notch in phase 2 [20]. This was not found endocardially or in control patients. They 
could not, however, demonstrate any loss of the AP dome and shortening of the epicardial 
action potential and instead found a MAP and repolarisation of longer duration in the 
epicardium compared with endocardium due to delayed dome formation. Although this could 
account for the reversal of the gradient in phase 3 necessary for the typical inverted T-wave, it 
raises doubt over the repolarisation theory. Abnormal MAPs were recorded in neighbouring 
epicardial sites over about a 2 cm radius of the RVOT but not in other sites in the RV anterior 
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wall and LV anterior and lateral wall. Although a novel in vivo demonstration of alteration of 
MAPs in BrS, the recordings made from corresponding epicardial and endocardial sites were 
not done simultaneously, with the epicardial MAPs being collected during open chest surgery.
 
 
Figure 1: The repolarisation hypothesis: Enhanced ITO expression in epicardium compared with endocardium 
results in a spike and dome AP morphology in the epicardium under normal circumstances (A). With reduction in 
sodium current, the amplitude of the phase 0 upstroke is reduced. Due to enhanced epicardial ITO expression, the 
phase 1 downstroke reduces the opening probability of calcium channels responsible for the early phase 2 plateau. 
This results in loss of the AP dome (B). This creates a transmural gradient between the endocardium and 
epicardium. This is thought to cause saddleback or coved ST elevation with the T wave remaining positive. Loss of 
the dome in some areas of epicardium and preservation in others facilitates phase 2 re-entry resulting in a closely 
coupled extrasystole at the site of epicardial AP dome abbreviation (C). Fig 1D shows the enhanced epicardial AP 
spike and dome with prolongation beyond the endocardial AP, demonstrating how this can have a corresponding 
surface ECG representation of both coved ST elevation and T wave inversion.                                           
In support of ITO being a key channel involved in the Brugada ECG pattern, the right ventricle 
has a higher density of this channel compared with the left ventricle and it is suggested that the 
thinner endocardium of the right ventricle relative to its epicardium results in a more marked 
spike and dome pattern in this region [21]. The marked prevalence of the syndrome in males 
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compared with females may also be explained by an overall increased expression of ITO in men 
[22]. The administration of quinidine, an effective ITO blocker, can lead to normalisation of the 
ECG and has suppressed arrhythmic activity in experimental models and human patients [23-
26]. The normalisation of the ECG at increased heart rates may be due to the slow reactivation 
kinetics of ITO  rendering it inactive at lower diastolic intervals leading to restoration of the 
epicardial action potential dome. However, exaggeration of the Brugada ECG changes at higher 
heart rates has also been observed.                                                                             
An outward shift in the balance of currents in the early phase of the action potential could 
account for the abbreviated epicardial action potential. Thus theoretically, a reduction in INa or 
the L-type calcium channel, an increase of ITO and/or any time dependent potassium current 
could result in the observed ECG pattern. For instance, sodium channel blockers can reveal the 
Brugada ECG and acetylcholine, which suppresses ICa and increases potassium current, can 
augment these changes. SCN5A, the gene encoding for the α subunit of the Nav1.5 voltage 
gated sodium channel and in which a loss of function mutation is seen in about 20% of Brugada 
patients, is more abundantly expressed in endocardium compared with epicardium [27]. This 
results in a lower upstroke velocity in the epicardial action potential which, together with 
increased ITO expression, generates normal transmural heterogeneity. Reduced sodium current 
with preserved outward potassium current would be expected to increase the transmural 
gradient.
Mode of Onset of Ventricular Arrhythmia                                                                       
The phenomenon of phase 2 re-entry triggering arrhythmic activity in the human right ventricle 
in vivo was first demonstrated by Thomsen et al. 83% of their study patients (not affected by 
Brugada syndrome) showed J-point elevation, ST elevation and T-wave changes in the sinus 
beat preceding ventricular extrasystoles and non-sustained ventricular tachycardia [28]. The 
mean coupling intervals of these extrasystoles was 300 to 505 msecs rather than the short 
coupling intervals expected of phase 2 re-entrant beats. It was argued that this may be due to the 
initial phase 2 re-entrant beat being concealed in the T wave of the preceding sinus beat, with 
the coupling interval of the following extrasystole being measured [29].                              
The mode of onset of ventricular fibrillation in Brugada patients with ICDs was studied by 
Kakashita et al. 33 episodes of spontaneous VF in seven patients were analysed [30]. Before VF 
onset, frequent ventricular extrasystoles were observed in the majority of episodes. These 
extrasysloes were almost identical to the initiating beat of VF. In the remaining episodes, 
preceding extrasystoles were not seen but the initiating beat of VF was morphologically similar 
to extrasystoles observed on remote occasions. Different VF episodes in the same patient were 
initiated by almost identical extrasystoles, and in two patients, initiating extrasystoles were 
morphologically similar, all suggesting a common ventricular focus. Coupling intervals were on 
average 388 ms, close to the end of the T wave, rather than the short intervals expected of those 
resulting from phase 2 re-entry. Kasanuki et al also documented >300 msec coupling intervals 
but also reported an increase in ST elevation in right praecordial leads prior to VF onset [31], 
suggesting that the ST changes and extrasystoles are linked by a common mechanism.
In the same year that Thomsen et al published their findings, however, Coronel et al presented 
an experimental data on the explanted heart of a 34 year-old male Brugada patient, who had 
undergone transplantation due to a high incidence of VF [19]. Using epicardial strips and non-
contact endocardial mapping, they failed to demonstrate a transmural repolarisation gradient and 
instead showed conduction delay in the right ventricular outflow tract, with the first beat of 
induced VF having a subendocardial, rather than subepicardial origin. Although ST elevation 
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was not present during mapping, computer simulations demonstrated that RV conduction delay 
alone in this case could result in a typical Brugada ECG, without there being alteration in action 
potential duration, lending support to the other main theory in BrS, the depolarisation 
hypothesis.
The  Depolarisation   Hypothesis                                                                            
This theory proposes that conduction delay in the RVOT results in unidirectional block leading 
to re-entry. If the RVOT AP is delayed in relation to that of the RV body, a voltage gradient 
develops between the two sites with the more positive membrane potential in the RV body 
(source) driving intercellular  current to the RVOT (sink). The circuit is completed by 
extracellular current from the RVOT to the RV, inscribing a positive deflection on the ECG (J 
point and ST elevation). This source-sink mismatch is then reversed with the delayed upstroke 
of the RVOT AP and as the RV repolarises, the more positive gradient in the RVOT drives the 
intercellular current to the RV, with the extracellular current now travelling from the RV to the 
RVOT, inscribing a negative deflection on the ECG (T-wave inversion) (Figure 2). The delayed 
conduction can lead to regions of functional block facilitating re-entry.
Figure 2: The depolarisation hypothesis: Activation is delayed in the RVOT. Prior to the onset of the AP in the 
RVOT, the RV, having depolarised, acts as a source of current (i). This current travels to the RVOT, acting as the 
sink, inscribing a positive deflection on the ECG (in the right praecordial leads).Once the RVOT depolarises and 
the RV is repolarising, the RVOT now acts as the source of current with the RV acting as the sink (ii). This reversal 
in   the   direction   of   current   flow   inscribes   a   negative   deflection   on   the   ECG   (negative   Twave).
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The prolongation of the PR interval and QRS duration in a significant proportion of Brugada 
patients has lent some support to the concept of conduction disturbances [33]. There has also been 
compelling   evidence   from   signal   averaged   ECG,   body   surface   mapping,   tissue   doppler 
echocardiography and invasive electrophysiological studies.                                    
Late potentials, representing delayed ventricular depolarisation, are prevalent in Brugada patients 
and have been found to coincide with spontaneous and pharmacologically induced ST elevation. 
Eckardt  et al performed  signal averaged  ECGs, body surface  mapping and programmed 
ventricular stimulation studies on sixteen Brugada patients with type 1 ECG changes at baseline, 
who had suffered syncope or aborted sudden cardiac death [10]. A larger area of ST elevation was 
found in Brugada patients compared with control patients, which increased after ajmaline 
administration. Late potentials were found in the majority. These two findings were correlated to 
the ease of VT inducibility in these patients. Takami et al found an increased incidence of late 
potentials among patients with coved ST elevation, a group generally accepted to be at higher 
risk, compared with saddleback ST elevation [12]. Antzelevitch has pointed out, however, that 
although late potentials are generally thought to reflect delayed depolarisation, they could also 
actually reflect either the exaggerated second upstroke of the epicardial action potential after the 
marked downstroke due to ITO repolarising current in phase 1 or the concealed phase 2 re-entry 
generated extrasystole(s) which has failed to trigger arrhythmia [29].                          
Nagase et al also found delayed potentials on the epicardial surface of the RVOT, using a wire 
inserted into the conus branch of the right coronary artery [5]. These coincided with later 
potentials recorded on signal averaged ECG. The same group then studied the ARIs and 
repolarisation times (RT) in the RVOT endocardium and epicardium simultaneously during 
ventricular stimulation studies using the conus branch epicardial recordings. Ten of the nineteen 
patients in this latter study had a type 1 ECG at baseline and nine developed type 1 changes 
following pilsicainide administration. They found longer ARIs and RTs in the epicardium 
compared with endocardium in Brugada subjects with a type 1 ECG at baseline. Shorter 
epicardial ARIs and RTs compared with endocardial repolarisation times were found in the 
control subjects as expected, and in Brugada patients with normal ECGs at baseline. In the latter 
group of patients, the epicardial ARIs and RTs were preferentially prolonged after pilsicainide, 
becoming longer than the endocardial ARIs and RTs, which remained the same. They were 
unable to demonstrate an accentuation of the epicardial AP notch, loss of the dome nor any 
shortening of the epicardial action potential but postulated that the latter could be because not all 
of the RVOT was studied and there may have been shortening in some areas and prolongation in 
others. Significantly longer activation times were also seen in Brugada patients with baseline type 
1 ECGs compared with those who had normal ECGs.                                       
Tukkie et al hypothesised that activation delay in a particular area would cause delayed 
contraction which would be detected by tissue Doppler echocardiography [33]. They studied 
contraction timing and contractile force in sixteen Brugada patients at baseline and post flecainide 
administration. All these patients had normal 2D echocardiograms. Delayed RV contraction 
occurred and corresponded to ST elevation in patients with type 1 changes at baseline, and those 
who developed these changes with flecainide. A marked impairment of tissue systolic velocities, 
reflecting contractile force, was not detected in these patients, suggesting that selective action 
potential shortening was not a factor here. However, reduced ejection times were also observed in 
the RV compared with the LV. This is not seen in patients with right bundle branch block where 
there is known activation delay in the right ventricle so may imply some level of action potential 
shortening in the RV of the Brugada patients.                                                                               
Electrophysiological testing in humans has also identified conduction abnormalities such as 
prolongation of the His-ventricular (HV) interval and Corrado et al demonstrated that the latest 
endocardial ventricular electrogram was from the RVOT [36]. Kanda et al found that patients 
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with readily inducible VF had a longer QRS duration, a higher incidence of late potentials, longer 
HV intervals and a longer conduction time from the RVOT to the left ventricle compared with 
non-inducible group [32]. Most of the arrhythmias were induced by extrastimuli applied to the 
RVOT and the degree of depolarisation abnormalities was thus linked to the risk of ventricular 
arrhythmia. However, a number of recent population based studies have shown that VT/VF 
inducibility at EP study does not necessarily establish risk for arrhythmic events in Brugada 
patients, indicating that more sophisticated strategies are necessary to identify high risk substrates 
in   this   disease.                                                                              
Postema et al performed RV endocardial mapping studies in type 1 and 2 Brugada patients [34]. 
They demonstrated conduction slowing and abnormal conduction velocity restitution in the right 
ventricle (with no significant regional differences) and showed that repolarisation characteristics 
were similar in Brugada patients and controls. In addition, they found not only broader but also 
more fractionated electrograms in the RV, citing discontinuous conduction, possibly due to subtle 
structural abnormalities leading to reduced intercellular coupling, as a pathophysiological aspect 
of   the   disease.                                                                          
In a recent non-invasive study, it was highlighted that these depolarisation abnormalities could 
lead to repolarisation abnormalities [35]. At baseline, the Brugada patients they studied already 
had longer P, PQ and QRS intervals than controls, and vectorcardiogram and body surface 
mapping data found more conduction slowing in this group on ajmaline administration, during 
which the type 1 ECG was elicited. No repolarisation abnormalities were found at baseline: QT, 
QTC  and Tpeak-Tend  intervals were similar between Brugada patients and controls, and the 
conduction slowing was accompanied by JT interval shortening, representing a shortening of the 
duration of repolarisation. They proposed that the abnormal repolarisation resulting in an inverted 
Twave follows on from abnormal depolarisation.                                                           
A high resolution non-contact endocardial mapping technique was utilised in a recent study by 
our group and demonstrated significant regional conduction delays, a reduction in the activation 
gradient and the formation of lines of functional conduction block in the anterolateral free wall of 
the RVOT compared with the RV body and apex of Brugada patients [40]. Fractionated 
electrograms,   suggesting   tissue   discontinuities,   were   also   found   in   this   area.   Wavefront 
fragmentation along these areas of functional conduction block, were shown in isochronal maps 
to initiate polymorphic VT and subsequent degeneration into VF in 5 patients. There were also 
steep restitution gradients in the RV reflecting repolarisation abnormalities in the endocardium 
that would contribute to the arrhythmic substrate. Epicardial parameters were not measured in this 
study. These conduction delays could account for the fragmented QRS identified on filtered 
ECGs by Zipes' group which has been correlated with an increased risk of clinical VF events [37]. 
These studies further support the notion that a level of structural derangement may be a facet of 
BrS, and the potentially complex relationship between tissue and ion channel abnormalities is 
open   to   debate.                                                                            
The Role of Ion Channel Mutations and Structural Derangements                              
Despite a recognised autosomal dominant pattern of inheritance, mutations predominantly in 
sodium channel genes have only been described in 30% of the Brugada population [38]. The 
heterogeneous genetics of BrS may give rise to the clinical spectrum of the phenotype; with 6 
genes linked to the condition at the time of writing. These include loss-of-function mutations in 
the cardiac sodium channel gene, SCN5A [39], and the GPD1-L gene [40], encoding for the 
glycerol-3-phosphate-dehydrogenase 1-like protein, dramatically altering phase 0 of the cardiac 
action potential. An overlap syndrome due to loss-of-function mutations in genes encoding the 
cardiac L type calcium channel (CaCNCA1C and CACNB2) resulting in a Brugada syndrome 
phenotype   combined   with   shorter-than-normal   QT   intervals   have   been   reported   [41]. 
Furthermore, a mutation in KCNE3 encoding ITO, the early transient outward potassium channel 
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current, has recently been described [42]. This leaves open the question regarding other 
pathophysiological   processes.                                                          
Although a structurally normal heart is still required as a diagnostic criterion-there is emerging 
evidence that this not the case. A number of studies have demonstrated fibrosis in the Brugada 
right ventricle suggesting a degenerative process which may be genetic, inflammatory or infective 
in origin. This fibrosis may be due to premature ageing of myocytes arising from abnormal ion 
channel kinetics as described in the SCN5A heterozygotic mouse [43-44]. It could explain the 
recent MRI data suggesting RVOT dilatation in BrS cases [45-46]. Such a fibrotic process will 
promote conduction delays in the RV and could explain the coved ST elevation of the Brugada 
ECG   independent   of   specific   ion   channel   mutations   promoting   transmural   repolarisation 
gradients. As described above, invasive mapping studies of the Brugada RV have confirmed 
significant conduction delays and computer simulations incorporating these delays can reproduce 
the characteristic surface ECG features [19]. These conduction abnormalities could also increase 
the arrhythmogenicity of the substrate through promoting conduction block and re-entry or 
causing destabilisation of VT into VF.                                                                                 
This identification of conduction delay in BrS raises a fascinating question, as to whether Na 
channel mutations which promote conduction slowing unmask the Brugada phenotype in a similar 
manner to a pharmacological Na channel blocker. Coronel's group points out that the identified 
Na channel mutations may simply be a co-factor in manifesting the disease but not the primary 
cause [47]. In order to identify Na channel mutations as the primary cause, one would have to 
show that SCN5A mutations are more prevalent in cases with less structural derangement, but this 
data does not yet exist. This concept relates to the 'multiple hit hypothesis' of pathophysiology 
where a number of factors may combine to create the disease substrate that manifests as a 
Brugada ECG. This has been demonstrated in long QT syndrome where a single potassium 
channel mutation and non-pathological ion channel polymorphism combine to create a malignant 
long QT phenotype but these independently, only result in minor ECG changes [48]. Due to the 
"physiological" reserve and compensatory ion channel currents, a single mutation or pathological 
change   may   remain   subclinical   until   another   factor/perturbation   tips   the   balance   into   a 
pathological   manifestation.                                                          
In   the   study   by   Postema   et   al   described   above,   where   increased   electrogram   duration, 
fractionation and activation delays were found in type 1 and 2 Brugada patients compared with 
controls: these findings became more marked with ajmaline in type 2 patients and conduction 
velocity (CV) restitution was found to be abnormal in type 1 patients, specifically with transverse, 
as opposed to longitudinal, propagation along myocardial fibres [34]. The abnormalities occurred 
with premature RV stimulation and not in sinus rhythm, not only confirming that the specialised 
conduction system is not involved in conduction delay in BrS, but that gross abnormalities in 
fibre orientation were not present in the BrS patients. This suggests that an increased intercellular 
coupling resistance (possibly due to tissue discontinuities like interstitial fibrosis affecting 
transverse impulse propagation more markedly) and/or reduced sodium current (possibly due to 
reduced sodium channel expression at the long axis of the myocardial fibre) could be responsible 
for the conduction delay. Interestingly, the presence or absence of an SCN5A mutation was not 
related to electrogram duration or degree of fractionation.                                                               
How   structural  abnormalities  could  mechanistically  contribute   to  the   signature   ECG  and 
arrhythmia in Brugada was demonstrated by Hoogendijk et al, who analysed the activation and 
repolarisation characteristics of the explanted heart of a patient with dilated cardiomyopathy and a 
loss-of-function mutation in SCN5A where right sided ST elevation was induced with ajmaline 
(the patient was not diagnosed with BrS and no ajmaline provocation had been performed in vivo) 
[49] The disappearance of local activation resulted in monophasic ST elevation in basal RV 
epicardium, where structural abnormalities (subepicardial adipose and fibrous tissue) were found. 
Reduction of INa only resulted in the signature Brugada sign following the  incorporation of 
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structural discontinuities into a computer model and appeared to be due to excitation failure and 
activation delay in the subepicardium due to current to load mismatch. This observation leads to 
an alternative mechanistic explanation for both the classic ECG pattern and arrhythmia, with 
excitation failure in RV subepicardium causing ST elevation, activation delay at neighbouring 
sites causing the negative T wave, and conduction block leading to re-entrant arrhythmia.
Is the Brugada Syndrome a Form of Cardiomyopathy?                                    
The   suggestion   that   BrS   may   actually   be   a   form   of   arrhythmogenic   right   ventricular 
cardiomyopathy   (ARVC),   particularly   in   view   of   the   increasing   evidence   of   structural 
abnormalities, has been raised. Significant overlap between the two conditions does exist: 
ajmaline has provoked type 1 changes in ARVC patients [50], and fibrofatty replacement of 
cardiac myocytes has been reported in patients diagnosed with BrS [51-52]. It is noteworthy, 
however, that genes associated with ARVC have not been found in Brugada patients. In 1996 
Corrado et al investigated members of a single family who possessed the type 1 ECG [53]. 
Cardiac histopathological examination in the proband revealed myocardial atrophy, transmural 
fatty replacement, interstitial fibrosis (including fibrosis involving the specialised conducting 
tissue), although no wall thinning or inflammatory infiltrates associated with classical ARVC 
were seen. An older sibling had moderate RV dilatation, apical trabecular changes and his right 
endomyocardial biopsy showed moderate fibrofatty replacement. Some other members of the 
pedigree had mild to moderate RV and/or RVOT dilatation, wall motion abnormalities and a 
trabecular pattern on echocardiography. The findings in this family, although not typical of 
classical ARVC, possess enough pathological features to suggest that there may be a relationship 
between the two diseases, illustrating the issue of diagnostic classification in the presence of both 
a typical type 1 ECG and marked structural abnormalities.                                 
The Role of the Autonomic Nervous System and Other Modulating Factors                          
A significant proportion of Brugada patients develop ventricular arrhythmias in the resting state 
or asleep, during which parasympathetic tone predominates. The typical ECG signs are unmasked 
or exacerbated by vagal stimulation, anti-adrenergic and parasympathomimetic drugs, and 
attenuated by exercise and isoproterenol infusion [31, 54-57]. In some reports, VF was inducible 
only upon edrophonium (a parasympathomimetic agent) administration, and in other cases, 
rendered noninducible with isoproterenol [31]. The high frequency component of heart rate 
variability, representing parasympathetic activity, was observed by Mizumaki et al to be increased 
in patients exhibiting spontaneous augmentation of ST elevation [56], and by Kasanuki et al to 
suddenly increase prior to the onset VF in 2 patients [31].                                   
In a study by Babaee Bigi et al, 13 out of 28 patients with a type 1 Brugada ECG pattern were 
considered to have cardiac autonomic neuropathy, based on 2 non-invasive tests of sympathetic 
and parasympathetic function [58]. 11 out of these 13 neuropathic patients had a history of 
cardiac events compared with only 2 of the 15 patients without autonomic dysfunction. Another 
group identified abnormal regional sympathetic innervation resulting in a relative dominance of 
parasympathetic activity in the hearts of Brugada patients (the majority with type 1 or type 2 
ECGs and arrhythmic events) by examining myocardial adrenergic innervations (utilising 123I-
MIBG-SPECT) and presynaptic noradrenaline recycling on PET [59-60].                       
Although autonomic dysfunction is not a prerequisite of BrS, it appears to be an important 
modulating factor in baseline ECG and arrhythmia occurrence. Why this is the case has not been 
elucidated but effects on the activity of ITO and the L-type calcium channel predominant during 
phase 2 of the action potential have been suggested [59, 61]. Effects on phase 2 are particularly 
noteworthy as together with sodium current, intracellular calcium dynamics play a key role in 
restitution kinetics, an important factor in the development of VF [62].                               
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Pyrexia has also been seen to unmask the characteristic ECG pattern and there are case reports of 
fever induced polymoprphic VT in Brugada patients [63-65] and one of ultimately fatal incessant 
VT in a patient with intractable fever [66]. Dumaine et al found that the Thr 1620 Met missense 
mutation in SCN5A rendered the sodium channel temperature sensitive, with faster decay and 
slower recovery from inactivation compared with the wild-type channel in vitro at increasing 
temperatures [67]. Further mutations rendering the activation and inactivation kinetics of the 
sodium channel temperature sensitive have been identified since [63-65,68]. Expected to affect 
sodium current in vivo, it has not been shown how they contribute mechanistically to arrhythmia.
Conclusions
Both repolarisation and depolarisation abnormalities probably contribute to arrhythmogenesis in 
the Brugada syndrome. Early repolarisation could cause phase 2 re-entry resulting in closely 
coupled extrasystoles initiating VT/VF. Conduction delay due to abnormal ion channel kinetics 
and subtle structural derangements could contribute to this dispersion of repolarisation and 
provide the substrate for the maintenance of ventricular arrhythmia. These elements may be 
present to a variable extent in each individual patient, modulated by factors such as vagal tone and 
pyrexia, and account for both the different degrees of J point elevation on surface ECG. The 
embryological development of the RVOT and structural changes with age may also lead to 
intercellular uncoupling allowing repolarisation and depolarisation abnormalities to surface and 
contribute to individual variation in disease expression.                                           
These issues are also important in the newer J wave disorders responsible for primary VF which 
are the pathological extension of a normal electrocardiographic variant. Their aetiology probably 
mirrors that of BrS arising from abnormal ion channel behaviour during phase 0 and phase 1 of 
the action potential as well as potential dissociation between epi and endocardial repolarisation 
creating transmural voltage gradients. Indeed BrS may simply reflect a localised RV variant of an 
extreme form of J point elevation in a spectrum of early repolarisation disorders. These conditions 
provide an important clinically relevant experimental paradigm which could open the door to new 
approaches in the treatment and prevention of lethal ventricular arrhythmias.                               
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